ENZYVANT SCIENCES
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
ENZYVANT SCIENCES
Industry:
Biopharma Biotechnology Health Care Medical
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.enzyvant.com
Total Employee:
11+
Status:
Active
Contact:
+41612254202
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Content Delivery Network
Similar Organizations
ApaTech
ApaTech is an orthobiologics company producing synthetic bone repair materials.
Autolomous
Autolomous is an biotechnology company engaged in manufacturing pragmatic digital solutions for cell and gene therapy.
Biomeb
Biomeb is a biotechnology company that provide personalized medicine for prevention, diagnosis and treatment of different pathologies.
CELLnLIFE
CELLnLIFE develops stem cell therapy for the treatment of rare and intractable diseases.
Certis USA
Certis USA is a biotechnology company specializing in biological product development solutions.
ERS Genomics
ERS Genomics is a biotechnology company to provide broad access to the foundational CRISPR-Cas9 intellectual property.
Genea
Genea provides assisted reproductive technology products and services alongside its subsidiaries.
GlycoMar
GlycoMar is a biotechnology company developing products for the human healthcare and personal care markets.
GPC Biotech
GPC Biotech is a German biopharmaceutical company that discovers and develops anticancer drugs.
Henry Ford Health System
Henry Ford Health System (HFHS) is one of the nation’s leading comprehensive, integrated health systems.
Igen Biotech
Igen Biotech is a biotechnological company that translates biomedical research into practical and marketable medical devices and services.
Inatherys
Inatherys is a biotechnology company developping monoclonal antibodies for the treatment of cancers and inflammatory diseases.
LifeArc
LifeArc is an independent life science medical research charity committed to drastically improving positive patient outcomes everywhere.
NeoDynamics
This company is a Swedish medical technology company focused on improving the diagnosis and treatment of breast cancer.
Neurotec Pharma
Neurotec Pharma is focused on developing new treatments for acute and chronic central nervous system (CNS) diseases.
OROX BioSciences
OROX BioSciences is a biotechnology start-up focused on the rapid discovery and development of novel small molecule medications.
OXOlife
Oxolife is a biotechnology company in the clinical phase of development.
Oxxon Therapeutics
Oxxon Pharmaccines Ltd., an Oxford, UK-based biotech company focused on immunotherapies.
Pharmaceutical Biotechnology
Pharmaceutical Biotechnology focuses on the development and implementation of new biotech projects with high market potential.
Procella Therapeutics
Procella Therapeutics is an early stage biotechnology company focused on developing cardiac stem cell technology.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Protomer Technologies
Protomer Technologies is a biotechnology company that focuses on metabolic diseases.
R&D Systems
R&D Systems is a product and services agency bringing together resources for Cell Biology research.
Radiopharma
Radiopharma engages in nuclear medicine and molecular imaging for the diagnosis and treatment of several diseases.
Retina Implant
Retina Implant is a biotech company which develops subretinal implants for partially sighted and blind patients.
Stemmatters
Stemmatters is a biotechnology company focused on regenerative medicine.
Wellcome Trust
Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health.
Xenova
Xenova publicly quoted biotechnology company focused on the development of novel drugs to treat cancer and addiction.
Current Employees Featured
Official Site Inspections
http://www.enzyvant.com Semrush global rank: 5.51 M Semrush visits lastest month: 1.55 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Enzyvant Sciences"
Enzyvant Announces Merger with Altavant - Yahoo Finance
Dec 6, 2022 Combined company has full range of capabilities required to advance bold science for rare diseases in immunology and cardiopulmonologyCARY, N.C., Dec. 06, 2022 (GLOBE …See details»
Enzyvant Announces Merger with Altavant - GlobeNewswire
Dec 6, 2022 A nimble and unique organization, Enzyvant has a full range of capabilities spanning non-clinical and clinical development and commercialization and is developing in …See details»
Enzyvant Sciences - Crunchbase Company Profile
Organization. Enzyvant Sciences . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. ... Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare …See details»
Sumitomo Pharma Subsidiary Companies in the U.S., Including …
Apr 3, 2023 A nimble and unique organization, Enzyvant has a full range of capabilities spanning non-clinical and clinical development and commercialization and is developing in house …See details»
Inside The Altavant/Enzyvant Self-Made Merger
Dec 21, 2022 Enzyvant’s allogeneic processed thymus tissue–agdc, RETHYMIC, was approved for the treatment of congenital athymia in pediatric patients in 2021. ... its lead candidate,” says Symonds. Where there was no …See details»
Enzyvant Stages NC HQ for Rare-Disease Battles
Enzyvant Therapeutics, Inc. and Altavant Sciences, Inc., both wholly owned subsidiaries of the global biopharmaceutical giant Sumitovant Biopharma Ltd., today announced a merger to form …See details»
Enzyvant Merges with Altavant to Advance Therapies for Rare …
Dec 7, 2022 Enzyvant is developing an in-house regenerative medicine manufacturing facility in North Carolina that is expected to be completed in the second half of 2024. The facility will …See details»
More biotech jobs, company HQ coming to Triangle in life science …
Dec 6, 2022 Enzyvant Therapeutics, Inc. and Altavant Sciences, Inc., both wholly owned subsidiaries of the global biopharmaceutical giant Sumitovant Biopharma Ltd., today …See details»
Enzyvant Announces Merger with Altavant | American …
Dec 6, 2022 The combined company retains the name Enzyvant and is equipped with a full range of capabilities spanning non-clinical and clinical development and commercialization …See details»
Enzyvant and Altavant announce merger to accelerate rare
Dec 8, 2022 The combined company, which retains the name Enzyvant, will have a full range of capabilities required to advance ‘bold science’ for rare diseases in immunology and …See details»
Enzyvant Announces Merger With Altavant - Drug Development …
A nimble and unique organization, Enzyvant has a full range of capabilities spanning non-clinical and clinical development and commercialization and is developing in-house manufacturing. …See details»
Enzyvant Company Profile - Office Locations, Competitors ... - Craft
Enzyvant is a company developing transformative therapies for people with rare diseases. Its pipeline includes investigational regenerative medicine therapies for T cell–implicated …See details»
Enzyvant Announces Merger with Altavant - DistilINFO LifeSciences
Dec 12, 2022 A nimble and unique organization, Enzyvant has a full range of capabilities spanning non-clinical and clinical development and commercialization and is developing in …See details»
Enzyvant Receives 2022 Rare Impact Industry Innovation
Jun 27, 2022 Enzyvant Receives 2022 Rare Impact Industry Innovation Award from the National Organization for Rare Disorders (NORD) for Novel, Tissue-Based Therapy to Treat Ultra-Rare, …See details»
Enzyvant Announces Merger with Altavant - BioSpace
Dec 6, 2022 A nimble and unique organization, Enzyvant has a full range of capabilities spanning non-clinical and clinical development and commercialization and is developing in …See details»
Enzyvant Announces Plans to Expand Regenerative Medicine …
Apr 21, 2022 Enzyvant. State-of-the-art facility will expand capacity for producing tissue-based and additional regenerative medicines. CAMBRIDGE, Mass. and BASEL, Switzerland, April …See details»
Enzyvant Receives 2022 Rare Impact Industry Innovation Award …
Jun 27, 2022 Company honored for its work on RETHYMIC® (allogeneic processed thymus tissue-agdc), a one-time, treatment for congenital athymia, an ultra-rare, severe …See details»
Enzyvant Announces Plans to Expand Regenerative Medicine …
“Enzyvant is committed to ensuring scalable GMP manufacturing for RETHYMIC ® (allogeneic processed thymus tissue-agdc), and we’re looking ahead to potential needs in other …See details»
Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic
Sep 10, 2021 Enzyvant’s RETHYMIC ® (previously RVT-802) is a one-time tissue-based regenerative therapy approved by the U.S. Food and Drug Administration for pediatric …See details»
Enzyvant Announces Plans to Expand Regenerative Medicine
Apr 21, 2022 Enzyvant is a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases. The company’s first commercial product is U.S. …See details»